The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.50
Bid: 19.00
Ask: 20.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.263%)
Open: 19.50
High: 19.50
Low: 19.50
Prev. Close: 19.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

20 Dec 2018 17:20

RNS Number : 1932L
Renalytix AI PLC
20 December 2018
 

Renalytix AI plc

("RenalytixAI" or the "Company") 

 

Director/ PDMR Shareholding

 

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 112 pence per share.

 

Following this purchase, Mr Mills is interested in 9,199,568 Ordinary Shares representing 17.09% of the total voting rights in the Company.

 

Enquiries:

 

Renalytix AI plc

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR or Tel: +1 646 397 3970

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)

 

Tom Salvesen / Mia Gardner (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

     

 

 

  

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Harwood Capital LLP (Harwood) as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Christopher Mills, non-exec director of the issuer and director of NASCIT and Oryx International Growth Fund Ltd

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Renalytix AI plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.25 pence each

 

 

 

Identification code

GB00BYWL4Y04

 

 

 

b)

 

Nature of the transaction

 

 

Share purchase

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

112.00 pence

3,168

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

3,168

 

 

- Price

£3,548.16

 

 

e)

 

Date of the transaction

 

20 December 2018

f)

 

Place of the transaction

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFKKDDOBDDFBB
Date   Source Headline
11th Mar 20248:10 amGNWForm 8.5 (EPT/RI) - Renalytix Plc
8th Mar 202412:14 pmRNSFORM 8 (OPD) - Renalytix plc
8th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
8th Mar 202410:57 amRNSForm 8.3 - Renalytix Plc
8th Mar 20247:37 amGNWForm 8.5 (EPT/RI) - Renalytix plc
7th Mar 20248:06 amGNWForm 8.5 (EPT/RI) - Renalytix Plc
6th Mar 20245:37 pmRNSForm 8.3 - RENALYTIX PLC
6th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
6th Mar 20247:56 amGNWForm 8.5 (EPT/RI) - Renalytix plc
5th Mar 20243:20 pmPRNForm 8.3 - Renalytix Plc
5th Mar 202412:00 pmRNSForm 8.5 (EPT/RI) - Renalytix plc
5th Mar 20248:08 amGNWForm 8.5 (EPT/RI) - Renalytix plc
4th Mar 20241:59 pmRNSForm 8.3 - Renalytix plc
4th Mar 20247:00 amRNSApproach from Possible Strategic Acquiror
1st Mar 20246:24 pmRNSGrant of Share Options - replacement
29th Feb 20247:00 amRNSUS Government coverage expanded
15th Feb 20247:00 amRNSHalf Year Report
9th Feb 20242:00 pmRNSRenalytix to Participate in the BTIG Conference
9th Feb 20247:00 amRNSCMS publishes Draft Local Coverage Determination
17th Jan 20247:00 amRNSUpdate on kidneyIntelX.dkd LCD Consideration
10th Jan 20247:00 amRNSNew published data for KidneyIntelXâ„¢
18th Dec 20237:00 amRNSIssue of Shares
15th Dec 20236:17 pmRNSResult of AGM
8th Dec 20236:14 pmRNSDirectorate Change
23rd Nov 20237:00 amRNSGrant of Share Options
17th Nov 20233:56 pmRNSPublication of Annual Report 2023 & Notice of AGM
14th Nov 20237:00 amRNSRenalytix Reports Financial Results for Q1 FY2024
7th Nov 20237:00 amRNSNotice of Results
30th Oct 20232:37 pmRNSAnnouncement of AGM and Publication of AR
24th Oct 20237:00 amRNSDirectorate change
17th Oct 20237:00 amRNSIssue of Shares
6th Oct 20237:00 amRNSUS Patent Office Allows Patent Claims for IP
3rd Oct 20233:13 pmRNSIssue of Shares
3rd Oct 20237:00 amRNSMedicare prices kidneyintelX.dkd at $950
28th Sep 20237:00 amRNSRenalytix Reports Full Year Fiscal 2023 Results
25th Sep 20237:00 amRNSNotice of Results
22nd Sep 20237:00 amRNSPayer coverage expansion of KidneyIntelX
7th Sep 20237:00 amRNSAppointment of Chief Business Officer
21st Aug 20237:00 amRNSBusiness Update
3rd Aug 20239:10 amRNSRSU vesting for employees
3rd Aug 20237:00 amRNSFormation of Clinical Advisory Board
21st Jul 20237:00 amRNSVector Pharma Middle East Distribution Agreement
17th Jul 20231:43 pmRNSIssue of Shares - Replacement
17th Jul 20237:00 amRNSIssue of Shares
7th Jul 20237:00 amRNSKidneyIntelX evidence presented at ADA
6th Jul 20235:38 pmRNSGrant of Share Options
3rd Jul 20237:00 amRNSDirectorate Change
30th Jun 20237:00 amRNSFDA Approves KidneyIntelX.dkd™
15th Jun 20237:00 amRNSPresentation of Scientific Data
9th Jun 20237:00 amRNSFinancial Results for Q3 of Fiscal Year 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.